Structural Determinants of Agonist-Selective Signaling at the sst2A Somatostatin Receptor-Reference-Cited by-同舟云学术

Structural Determinants of Agonist-Selective Signaling at the sst2A Somatostatin Receptor

Published:2011-05-01 Issue:5 Volume:25 Page:859-866
ISSN:0888-8809
Container-title:Molecular Endocrinology
language:en
Short-container-title:

Author:

Nagel Falko¹,Doll Christian¹,Pöll Florian¹,Kliewer Andrea¹,Schröder Helmut²,Schulz Stefan¹

Affiliation:

1. Department of Pharmacology and Toxicology (F.N., C.D., F.P., A.K., S.S.), University Hospital Jena-Friedrich Schiller University, D-07747 Jena, Germany;

2. Department of Pharmacology and Toxicology (H.S.), Otto von Guericke University, D-39120 Magdeburg, Germany

Publisher

The Endocrine Society

Subject

Endocrinology,Molecular Biology,General Medicine

Link

http://academic.oup.com/mend/article-pdf/25/5/859/10722259/mend0859.pdf

Reference23 articles.

1. Opportunities in somatostatin research: biological, chemical and therapeutic aspects.;Weckbecker;Nat Rev Drug Discov,2003

2. Treatment of acromegaly: future.;Donangelo;Endocrine,2005

3. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.;Oberg;Gastroenterology,2010

4. The role of somatostatin analogs in Cushing's disease.;van der Hoek;Pituitary,2004

5. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.;Bruns;Eur J Endocrinol,2002

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine;Nature Communications;2023-02-21

2. Neuroendocrine tumor theranostics;Cancer Science;2022-04-11

3. GPCR kinase knockout cells reveal the impact of individual GRKs on arrestin binding and GPCR regulation;Nature Communications;2022-01-27

4. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors;Molecular and Cellular Endocrinology;2021-05

5. Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects;Cancers;2021-04-10